|
|
|
Stem Cell Related Patent Number US6783775
| Title: | Serum-derived factor inducing cell differentiation and medical uses thereof | | Inventors: | Peled, Tony; Mevaseret Zion, Israel
Fibach, Eitan; Mevaseret Zion, Israel
Rachmilewitz, Eliezer A.; Jerusalem, Israel | | Summary: | Described herein is a biologically active serum-derived factor (SDF) having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm. Methods are disclosed by which the molecular weight of the SDF was determined via electron spray mass spectrometry and was found to be 316 Da. Further described is the complex of SDF with ceruloplasmin (CP) which is capable of inducing terminal cell differentiation of leukemic cells, thereby causing the cells to lose their ability to proliferate and their ability for self cell renewal. Claims of the invention include the means by which SDF or its complex with CP is capable of stimulating the proliferation of early, normal progenitor cells and inhibiting enhanced angiogenesis. Pharmaceutically acceptable compositions are disclosed, as are therapeutic applications in the inhibition of angiogenesis for the remission of tumors, for inducing terminal cell differentiation in leukemic cells, and for expanding hematopoietic normal stem and progenitor bone marrow transplants. | | Abstract: | The present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm. The molecular weight of said SDF was determined by electron spray mass spectrometry and is of 316 Da. SDF of the present invention or its complex with ceruloplasmin (CP) have several therapeutic properties. For example, SDF or its complex with CP is capable of inducing terminal cell differentiation of leukemic cells, which as a result, may lose their ability to proliferate and their ability for self cell renewal. Further, SDF or the complex with CP is capable of stimulating the proliferation of early, normal progenitor cells and inhibiting enhanced angiogenesis. In addition, SDF or its complex with CP is capable of ex vivo expanding normal stem and progenitor cells. The invention also relates to pharmaceutical composition comprising as active ingredient SDF or its complex and optionally further comprising pharmaceutically acceptable additives. Such pharmaceutical compositions may be for inhibiting enhance angiogenesis, for inducing remission of tumors, for maintaining tumor remission, and for expanding hematopoietic normal stem and progenitor bone marrow transplants. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6783775 | | Application Number: | US2001000986503 | | Date Filed: | 09/11/2001 | | Date Published: | 31/08/2004 | | Assignee: | Hadasit Medical Research Services and Development Ltd., Jerusalem, Israel |
|
|
